Prostaglandin E2 (PGE2) is a major cyclooxygenase metabolite of arachidonic acid and a potent modulator of a wide variety of cellular responses including vascular tone, febrile response as well as water and ion transport in the kidney. There is now firm evidence that most of PGE2's effects are mediated via specific guanine nucleotide regulatory protein coupled receptors designated EP1, EP2, EP3, and EP4. The EP3 receptor is the unique among the EP receptor family in that it is represented by multiple alternatively spliced variants generated by alternative splicing from a single gene of a common precursor mRNA. The principal hypothesis of this proposal is that differential expression of EP3 receptor splice variants on individual cell types results in differential activation of signaling pathways that determine the physiologic response of a target cell to PGE2. Implicit in this hypothesis is the notion that the EP3 receptor variants have functionally distinct tissue distribution, cellular expression, and intracellular compartmentalization as well as distinct signal transduction properties. To test this hypothesis, in Specific Aim 1 we will determine the physiologic role of the EP3 receptor splice variants using an genetically modified mice strategy expressing a restricted repertoire of EP3 receptor splice variants. We will characterize phenotypic changes focusing on blood pressure, and vascular reactivity. Although the EP3 receptor has classically been characterized as a Gi coupled receptor that signals by lowering intracellular cAMP levels, recent studies suggest that EP3 alternative splice variants couple through other non-Gi signal transduction pathways.
In Specific Aim 2, studies will focus on the characterization of the EP3 receptor-mediated mechanism of cAMP independent signal transduction and its effect on gene transcription. We will examine the potential for this pathway to modulate gene expression using specific inhibitors and phosphorylation-specific antibodies in Western blot analysis, and promoter analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK046205-12
Application #
6845660
Study Section
Special Emphasis Panel (ZRG1-SSS-5 (01))
Program Officer
Rys-Sikora, Krystyna E
Project Start
1993-08-01
Project End
2007-01-31
Budget Start
2005-02-01
Budget End
2007-01-31
Support Year
12
Fiscal Year
2005
Total Cost
$288,789
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Ceddia, Ryan P; Lee, DaeKee; Maulis, Matthew F et al. (2016) The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice. Endocrinology 157:220-32
Natarajan, Chandramohan; Hata, Aaron N; Hamm, Heidi E et al. (2013) Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor. Mol Pharmacol 83:206-16
Downey, Jason D; Saleh, Sam A; Bridges, Thomas M et al. (2013) Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere. Bioorg Med Chem Lett 23:37-41
Zhang, Jian; Zou, Fangfang; Tang, Juan et al. (2013) Cyclooxygenase-2-derived prostaglandin Eýýý promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res 113:104-14
Shi, Ju; Wang, Qian; Johansson, Jenny U et al. (2012) Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann Neurol 72:788-98
Bartlett, Christina S; Boyd, Kelli L; Harris, Raymond C et al. (2012) EP1 disruption attenuates end-organ damage in a mouse model of hypertension. Hypertension 60:1184-91
Singh, Pratibha; Hoggatt, Jonathan; Hu, Peirong et al. (2012) Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells. Blood 119:1671-82
Chen, Lihong; Miao, Yifei; Zhang, Yahua et al. (2012) Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility. Arterioscler Thromb Vasc Biol 32:3024-32
Jewell, Mark L; Breyer, Richard M; Currie, Kevin P M (2011) Regulation of calcium channels and exocytosis in mouse adrenal chromaffin cells by prostaglandin EP3 receptors. Mol Pharmacol 79:987-96
Downey, Jason D; Sanders, Charles R; Breyer, Richard M (2011) Evidence for the presence of a critical disulfide bond in the mouse EP3? receptor. Prostaglandins Other Lipid Mediat 94:53-8

Showing the most recent 10 out of 52 publications